Lebrikizumab (Ebglyss) for atopic dermatitis in real-world care
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests how well lebrikizumab (Ebglyss), an approved treatment for moderate-to-severe atopic dermatitis (eczema), works in everyday clinical practice. It aims to see how the drug affects your symptoms and quality of life over time, helping guide better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old and weigh at least 88 pounds (40 kg).
- You have moderate-to-severe eczema, as rated by your doctor.
- Your doctor has decided to start you on Ebglyss (lebrikizumab) as part of your normal care.
- You have not used Ebglyss before.
- You are willing to fill out monthly online surveys about your symptoms.
- You are not pregnant or breastfeeding at the start of the study.
- You are not currently on another advanced treatment for eczema (except for a short course of steroids, cyclosporine, or a JAK inhibitor taken for 14 days or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests a new injected medicine, lebrikizumab, for people whose eczema mainly affects the face and neck. It aims to see if it can improve these hard-to-treat areas.
This study looks at how lebrikizumab, a biologic medicine for atopic dermatitis (eczema), affects the skin's microbiome (the natural community of microorganisms on your skin). It aims to see if changes in the skin's microbiome are linked to treatment response.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.